Literature DB >> 33748165

What's New in the Treatment of Systemic Lupus Erythematosus.

Stamatis Nick Liossis1,2, Chrysanthi Staveri1.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease with a variable presentation and manifestations ranging from mild to severe or even life-threatening. There is an ongoing and unmet need for novel, disease-specific, effective and safe treatment modalities. The aim of this review is to summarize data on SLE treatment that have emerged over the last 3 years. We will put emphasis on studies evaluating potential treatments on severe lupus manifestations such as lupus nephritis. Despite the existence of several therapeutic agents in SLE, the disease keeps causing significant morbidity. It is encouraging that a variety of therapeutic options are currently under investigation, although there are occasional trial failures.
Copyright © 2021 Liossis and Staveri.

Entities:  

Keywords:  B cell; clinical trial; lupus nephritis; systemic lupus erythematosus; treatment

Year:  2021        PMID: 33748165      PMCID: PMC7973110          DOI: 10.3389/fmed.2021.655100

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  7 in total

1.  Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria.

Authors:  Shudan Wang; Allan Spielman; Mindy Ginsberg; Michelle Petri; Brad H Rovin; Jill Buyon; Anna Broder
Journal:  Clin J Am Soc Nephrol       Date:  2022-07-26       Impact factor: 10.614

Review 2.  Lupus Academy: Keeping Education Live, Virtually.

Authors:  Julian Ball; Nicole Elzebroek; Eugene Pozniak
Journal:  J Eur CME       Date:  2021-12-14

Review 3.  Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.

Authors:  Edgar Carnero Contentti; Jorge Correale
Journal:  J Neuroinflammation       Date:  2021-09-16       Impact factor: 8.322

4.  Sexual Dimorphisms of Protein-Coding Gene Profiles in Placentas From Women With Systemic Lupus Erythematosus.

Authors:  Hui-Hui Li; Lin-Tao Sai; Shan Tian; Yuan Liu; Colman I Freel; Kai Wang; Chi Zhou; Jing Zheng; Qiang Shu; Ying-Jie Zhao
Journal:  Front Med (Lausanne)       Date:  2022-03-15

5.  Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.

Authors:  Christie Fanton; Richard Furie; Vishala Chindalore; Robert Levin; Isam Diab; Neha Dixit; Cat Haglund; Jacqueline Gibbons; Nathan Hanan; Daniel Dickerson; Jonathan Zalevsky; Brian L Kotzin
Journal:  J Transl Autoimmun       Date:  2022-03-28

Review 6.  Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.

Authors:  George Saitakis; Bart K Chwalisz
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

Review 7.  Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.

Authors:  Marlene Plüß; Silvia Piantoni; Björn Tampe; Alfred H J Kim; Peter Korsten
Journal:  Hum Vaccin Immunother       Date:  2022-05-19       Impact factor: 4.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.